About Actinogen Medical Ltd | ASX:ACW
Actinogen is a Phase 2, clinical-stage biopharmaceutical company developing a revolutionary new oral therapy for Alzheimer’s disease and cognitive impairment associated with depression.
This website uses cookies to improve performance, functionality and user experience. By agreeing to continue to browse our website, you are providing consent to the use of cookies. Please see our Privacy Policy for details on how we use cookies